Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics
Clinical Journal of the American Society of Nephrology · 2025
DOI: 10.2215/cjn.0000000967 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Journal of the American Society of Nephrology, 2025. Verfasst von Dana V Rizk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. Hauptthemen laut MEDLINE: Complement System Proteins, Kidney Diseases, Complement Activation, Complement Inactivating Agents. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Pharmacologic complement inhibition offers a promising therapeutic strategy for several complement-mediated kidney diseases. Yet, at present, nephrologists must rely on an incomplete toolkit of histopathologic and circulating biomarkers to assess complement activity in complement-mediated kidney diseases. Our clinical capacity to characterize and monitor pathologically dysregulated complement for disease prognosis, to inform patient selection, and to evaluate therapeutic efficacy severely lags behind the growing number of complement inhibitors under development. Reliable, sensitive complement biomarkers that are suitable for clinical assessment are needed for the timely and optimal implementation of existing and upcoming therapeutics. Despite this urgent need and growing research efforts, the repertoire of clinically available complement biomarker assays has proven refractory to expansion. This is, in part, due to a myriad of practical challenges limiting the information reliably interpreted from existing complement biomarkers and hindering the translation of novel biomarkers from research settings into the clinical pathology laboratory. In this article, the authors review commonly evaluated complement biomarkers within the context of an evolving therapeutic landscape, as well as the practical challenges related to their effective application. Noteworthy, emerging biomarkers are also discussed, along with the challenges in translating robust markers of complement activity from research settings into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
- Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
- Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
- Division of Rheumatology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
- Division of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
ORCID-Profile: Bradley P Dixon, Melvin Chan, H Terence Cook, Sydney C W Tang
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Rizk, D. V., Dixon, B. P., Chan, M., Cook, H. T., Frazer-Abel, A., & Tang, S. C. W. (2025). Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000000967
Vancouver
Rizk DV, Dixon BP, Chan M, Cook HT, Frazer-Abel A, Tang SCW. Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics. Clinical Journal of the American Society of Nephrology. 2025. doi:10.2215/cjn.0000000967
BibTeX
@article{Rizk2025,
author = {Rizk, Dana V and Dixon, Bradley P and Chan, Melvin and Cook, H Terence and Frazer-Abel, Ashley and Tang, Sydney C W},
title = {Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2025},
doi = {10.2215/cjn.0000000967}
}
EUVIMED